Scarica l'app Stockscreener
109.96
2.15%
-2.42
Dopo l'orario di chiusura:
110.20
0.24
+0.22%
Precedente Chiudi:
$112.38
Aprire:
$110.55
Volume 24 ore:
89,537
Relative Volume:
0.42
Capitalizzazione di mercato:
$738.07M
Reddito:
-
Utile/perdita netta:
$-14.99M
Rapporto P/E:
-53.21
EPS:
-2.0665
Flusso di cassa netto:
$-10.01M
1 W Prestazione:
-7.25%
1M Prestazione:
-5.49%
6M Prestazione:
+87.93%
1 anno Prestazione:
+156.32%
Intervallo 1D:
$108.84
$112.56
Intervallo di 1 settimana:
$108.84
$119.00
Portata 52W:
$42.51
$124.82
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Nome
Monopar Therapeutics Inc
Settore
Industria
Telefono
(847) 388-0349
Indirizzo
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
109.96 | 754.31M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Iniziato | Morgan Stanley | Overweight |
| 2025-11-14 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | Iniziato | Leerink Partners | Outperform |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-09-09 | Iniziato | BTIG Research | Buy |
| 2025-09-03 | Iniziato | Oppenheimer | Outperform |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-08-26 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-23 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-19 | Ripresa | Piper Sandler | Overweight |
| 2025-01-10 | Iniziato | Piper Sandler | Overweight |
| 2024-10-11 | Iniziato | Rodman & Renshaw | Buy |
| 2021-01-28 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie
Discipline and Rules-Based Execution in MNPR Response - Stock Traders Daily
Monopar Therapeutics shares technical analysis: $120.21 resistance in focus after rally - Traders Union
Monopar Therapeutics stock trades near record levels as investors react to insider selling and stron - ad-hoc-news.de
What's behind Monopar Therapeutics's latest 3.0% stock pullback? - Traders Union
Monopar Therapeutics director Kim Tsuchimoto sells $455,566 in shares By Investing.com - Investing.com Canada
Monopar Therapeutics (MNPR) director sells 4,090 shares after option exercises - Stock Titan
Monopar Therapeutics director Raymond Anderson sells $351,835 in stock By Investing.com - Investing.com Canada
Monopar (MNPR) insider sells at $110–113 after $30 option exercise - Stock Titan
Will Monopar Therapeutics stock regain momentum as oversold conditions limit further selling? - Traders Union
Monopar director Kim Tsuchimoto sells $455k in common stock By Investing.com - Investing.com Nigeria
Monopar Therapeutics director Raymond Anderson sells $351k in stock By Investing.com - Investing.com Canada
Monopar Therapeutics Director Kim R. Tsuchimoto Executes Six-Tranche Stock Sale Under Rule 10b5-1 Plan - Kalkine Media
Monopar Therapeutics (MNPR) CMO uses plan to exercise options - Stock Titan
Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common shares - Bitget
Monopar Therapeutics (MNPR) director plans $906K share sale - Stock Titan
Monopar Therapeutics stock resistance test: Key levels to watch - Traders Union
Monopar Therapeutics (MNPR) acting CMO plans 1-share sale - Stock Titan
Monopar (NASDAQ: MNPR) director to sell 6,284 shares - Stock Titan
Companies Like Monopar Therapeutics (NASDAQ:MNPR) Can Afford To Invest In Growth - webull.com
Monopar (MNPR) Quarter in Focus: EPS Clears the Reported Estimate in the Current Update; Trading Response: Shares Close 2.85% Lower in the Latest SessionInvestor Earnings Call - vinanet.vn
Monopar (MNPR) Latest: Ends Lower by 2.85% at $107.72 in the Latest Reading; Technical Setup: Price Remains Between $102.33 Support and $113.11 Resistance at the CloseBreak of Structure - vinanet.vn
MNPR drops as short-term selling pressure persists - Traders Union
Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $130 - Moomoo
What's behind Monopar Therapeutics's latest stock pullback? - Traders Union
Monopar (MNPR) Chart: Retreats 2.41% to $120.85 in the Latest Reading; Price Levels: $114.81 and $126.89 Define the Nearby Reference Levels under the Current SnapshotLeveraged ETF Flow - vinanet.vn
Monopar (MNPR) Earnings Report: EPS Beats Its Estimate for the Current Session; Session Move: The Stock Ends Up 4.02% in the Latest ReadingInterim Report - vinanet.vn
Monopar appoints medical affairs head, presents at liver meeting By Investing.com - Investing.com South Africa
Monopar appoints medical affairs head, presents at liver meeting - Investing.com
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLDThe Liver Meeting® 2026 - The Manila Times
Monopar (MNPR) Price Update: Rises 1.94% to $118.75 at the Close; Price Context: the $112.81 to $124.69 Range Remains in Focus in the Latest ReadingLate Stage Breakouts - vinanet.vn
Monopar (MNPR) Close in Focus: Ends Up by 0.70% at $117.30 for the Current Session; Technical Position - vinanet.vn
Monopar: Licensing Agreement, Rolling NDA Submission Serve As Catalysts For ‘Strong Buy’ - Seeking Alpha
(MNPR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Monopar Therapeutics (NASDAQ:MNPR) Cut to Sell at Wall Street Zen - MarketBeat
Zacks Research Downgrades Monopar Therapeutics (NASDAQ:MNPR) to Hold - MarketBeat
Equities Analysts Offer Predictions for MNPR FY2029 Earnings - MarketBeat
Buy Rating Reiterated on Monopar as ALXN-1840 Advances in Wilson Disease; $125 Price Target Maintained - TipRanks
Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald - marketscreener.com
Monopar downgraded to Neutral at Cantor (MNPR:NASDAQ) - Seeking Alpha
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Benzinga
MNPR Maintained by Barclays -- Price Target Raised to $128.00 - GuruFocus
MNPR Downgraded by Cantor Fitzgerald -- Price Target Raised to $119 - GuruFocus
Monopar Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Cantor downgrades Monopar stock on valuation after 90% rally - Investing.com
Cantor downgrades Monopar stock on valuation after 90% rally By Investing.com - Investing.com Canada
Boris Peaker Maintains Buy Rating on Monopar, Reaffirming Unchanged $130 Price Target on ALXN1840’s Strong Clinical and Regulatory Profile - TipRanks
Saturn V Capital shows sub-5% Monopar Therapeutics (MNPR) stake in 13G/A - Stock Titan
Monopar Therapeutics stock price target raised to $133 by BTIG - Investing.com Canada
MNPR Maintained by BTIG -- Price Target Raised to $133 - GuruFocus
BTIG Research Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) Stock - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
Monopar Therapeutics Inc Azioni (MNPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):